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Docetaxel is a standard chemotherapy for patients
with metastatic prostate cancer. However, the re-
sponse is rather limited and not all of the patients
benefit from this treatment. To uncover key mech-
anisms of docetaxel insensitivity in prostate cancer,
we have established docetaxel-resistant sublines. In
this study, we report that docetaxel-resistant cells
underwent an epithelial-to-mesenchymal transition
during the selection process, leading to diminished
E-cadherin levels and up-regulation of mesenchy-
mal markers. Screening for key regulators of an
epithelial phenotype revealed a significantly re-
duced expression of microRNA (miR)-200c and miR-
205 in docetaxel-resistant cells. Transfection of ei-
ther microRNA (miRNA) resulted in re-expression
of E-cadherin. Functional assays confirmed reduced
adhesive and increased invasive and migratory abil-
ities. Furthermore, we detected an increased sub-
population with stem cell-like properties in resis-
tant cells. Tissue microarray analysis revealed a
reduced E-cadherin expression in tumors after neo-
adjuvant chemotherapy. Low E-cadherin levels
could be linked to tumor relapse. The present
study uncovers epithelial-to-mesenchymal transi-
tion as a hallmark of docetaxel resistance. There-
fore, we suggest that this mechanism is at least
in part responsible for chemotherapy failure, with
implications for the development of novel
2188therapeutics. (Am J Pathol 2012, 181:2188–2201; http://
dx.doi.org/10.1016/j.ajpath.2012.08.011)
Systemic polychemotherapy, including the microtubule
inhibitor docetaxel, is the state-of-the-art treatment for
different types of cancer. Unfortunately, docetaxel-based
chemotherapy often encounters several undesirable ad-
verse effects, and many patients initially do not respond
to docetaxel or acquire resistance during treatment. Little
has been known about the molecular mechanisms re-
sponsible for initial or acquired docetaxel insensitivity in
prostate cancer, even though recent studies suggested
that STAT1,1 the kinase PIM1,2 and 3 tubulin3 might be
involved in this process. In castration-refractory prostate
cancer, docetaxel treatment is the first chemotherapy
that showed a significant benefit concerning survival,
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rum levels, and enhanced quality of life.4,5 However,
patient survival is prolonged just for a few months.6
Therefore, the identification of molecular mechanisms un-
derlying docetaxel resistance in prostate and other can-
cers becomes an issue of great interest.
It is well-known that cells in primary tumors that acquire
increased invasive and migratory abilities, in combination
with loss of adhesion molecule expression, are the source
and origin of metastases. These cells change from an epi-
thelial to a motile mesenchymal phenotype during a pro-
cess called epithelial-to-mesenchymal transition (EMT).
EMT is crucial for epithelial cancer cells to acquire an inva-
sive phenotype and has already been linked to a metastatic
state and poor prognosis in cancer.7,8 Key signals that lead
to EMT trigger expression of a variety of transcriptional
repressors, including ZEB1, ZEB2/SIP1, Snail, and
Twist.9–11 These repressors are the intracellular mediators
of EMT by binding to E-box elements of genes, such as
CDH1, that encode for the adhesion protein E-cadherin.
After binding, they recruit histone deacetylases and other
corepressors to facilitate transcriptional repression of E-
cadherin. Reduced E-cadherin expression is characterized
by loss of cell-cell adhesion, notably by disruption of the
cadherin-catenin complex along with other signaling
events, which, in turn, lead to loss of cell polarization and
the acquisition of a migratory mesenchymal phenotype.9,12
In addition, increased expression of mesenchymal markers,
such as vimentin and N-cadherin, is indicative of a morpho-
logical change.13 Recent studies have identified miRNAs,
especially members of the miR-200 family, as important regu-
lators of EMT.14,15 They repress ZEB1 and ZEB2 and enforce
the epithelial phenotype. These miRNAs can be down-regu-
lated in different types of cancer.16,17 Those studies have also
linked EMT and loss of E-cadherin with induction of stem cell-
like phenotypes in various cancers.18 In summary, EMT-driven
E-cadherin loss and cell morphological change to a mesen-
chymal phenotype are hallmarks of progression to invasive
and metastatic carcinomas. Therefore, we asked whether
these cellular processes can be a source of docetaxel resis-
tance and disease progression.
In the present study, we report that docetaxel resis-
tance is characterized by the appearance of EMT, which
is associated with a reduced expression of miR-200c and
miR-205. Docetaxel-resistant cells showed a reduced E-
cadherin and an increased vimentin expression accom-
panied by induced expression of stem cell markers com-
pared with parental cells. These molecular changes
resulted in the establishment of a highly aggressive do-
cetaxel-resistant cancer cell phenotype in vitro. Further-
more, we demonstrate that E-cadherin expression in vivo
decreases during chemotherapy and is associated with
disease relapse.
Materials and Methods
Cell Culture and Chemicals
Human prostate cell lines PC3 and DU-145 were ob-
tained from ATCC (Rockville, MD). Docetaxel-resistantcell lines PC3-DR and DU-145-DR were established in
the presence of increasing concentrations of docetaxel
(Sigma-Aldrich, St. Louis, MO) up to a final concentra-
tion of 12.5 nmol/L. Cell lines were cultured in RPMI
1640 medium supplemented with 10% fetal calf serum
(FCS) and 20 mmol/L glutamine. Human bone marrow
endothelial cells (HBMEC-60) were maintained in me-
dium 199, including glutamine, and 25 mmol/L HEPES
supplemented with 10% FCS and 10% human serum.
Prostate fibroblasts (PFs; patient code 172) were es-
tablished and cultured in Dulbecco’s modified Eagle’s
medium, low glucose, supplemented with 10% FCS
and 20 mmol/L glutamine. Images of cells were taken
using IC Capture software version 2.2 with an Olympus
CK2 microscope (Olympus, Vienna) equipped with an
Imaging Source Camera DFK31F03 (Imaging Source,
Bremen, Germany). The identity of the used cell lines
was confirmed by short tandem repeat analysis.
Western Blot Analysis
Western blot analysis was performed as previously
described.19 The following antibodies were used: anti-
glyceraldehyde-3-phosphate dehydrogenase (1:
100,000; Chemicon, Vienna), anti-E-cadherin (1:500;
Becton Dickinson, Heidelberg, Germany), anti-vimen-
tin (1:500; Santa Cruz Biotechnology, Santa Cruz, CA),
anti–Twist-1 (1:500; Santa Cruz Biotechnology), anti-
Snail (1:500; New England Biolabs, Ipswich, MA), and
anti-cleaved poly (ADP-ribose) polymerase (1:1000;
Promega, Madison, WI).
[3H]Thymidine Incorporation and MTT Assay
Cells were seeded at a density of 3.5  103 per well in
triplicate onto separate 96-well plates in the presence
or absence of docetaxel and incubated for 72 hours.
Thymidine incorporation was measured as previously
described.19 As an index of cell viability, an MTT assay
(Biomedica, Vienna) was performed according to the
manufacturer’s protocol.
Apoptosis Measurement
The percentage of apoptotic cells was measured after
incubation of cells in the absence or presence of do-
cetaxel for 72 hours or after double transfection with
miRNAs after 6 days by flow cytometry, as previously
described.19
Clonogenic and Spheroid Assay
Colony formation assays were performed as previously
described.20 For a spheroid assay, six-well plates were
coated with Matrigel (1:1 Matrigel/medium mix; Becton
Dickinson). Cells, 1  104, were seeded onto coated
wells, covered additionally with Matrigel, and incubated
for 14 days. Formed spheroids were harvested and for-
malin-fixed and paraffin-embedded (FFPE) for immuno-
histochemistry (IHC).
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Total RNA was isolated using the RNeasy mini kit (Qia-
gen, Hilden, Germany), and cDNA synthesis was per-
formed using a cDNA RT2 first-strand kit (Qiagen). EMT
array was performed on an ABI Prism 7900HT system
(Applied Biosystems, Carlsbad, CA) with four biological
replicates for each cell line on RT2 Profiler PCR-array
PAHS-090 plates (Qiagen), following the manufacturer’s
protocol. Quantitative RT-PCR (RT-qPCR) for confirma-
tion of regulated genes was performed as previously
described.19 TATA-Box–binding protein was chosen as
an endogenous expression standard. For E-cadherin, vi-
mentin, ZEB1, and ZEB2, TaqMan gene expression as-
says (Hs01013955_m1, Hs00185584_m1, Hs00232783_m1,
and Hs00207691_m1) were used.
miRNA Screening and Transfection
Total RNA was isolated using the miRNeasy mini kit
(Qiagen), and cDNA synthesis was performed using a
universal cDNA synthesis kit (Exiqon, Vedbaek, Den-
mark) following the manufacturer’s protocol. Specific
primers for miR-200c and miR-205 and primers for
SNORD44 and SNORD48, used for normalization, were
obtained from Exiqon. PCR products were measured
using the ABI Prism 7500 Fast RT-PCR System (Ap-
plied Biosystems). For miRNA transfection, hsa-miR-
200c, hsa-miR-205, and miRNA Mimic Negative Con-
trol were obtained from Dharmacon (Epsom, UK). Cells
were transfected twice during a period of 6 days with
25 nmol/L of miRNAs using Lipofectamine 2000 (Invit-
rogen, Vienna) reagent, according to the manufactur-
er’s protocol, and harvested for Western blot and flu-
orescence-activated cell sorting (FACS) analyses,
respectively.
TMA and IHC Data
To evaluate differences in E-cadherin expression be-
tween malignant and benign prostate tissue, we con-
structed a tissue microarray (TMA) of FFPE tissue blocks
of 14 patients with prostate cancer who underwent che-
motherapy with docetaxel before radical prostatectomy
and 14 untreated patients with prostate cancer. Both
groups were matched for Gleason score and age (see
Supplemental Table S1 at http://ajp.amjpathol.org). The
use of the archive samples was approved by the Ethics
Committee of Innsbruck Medical University. For each
selected case, three cancer tissue cores and three
benign cores were punched. The TMA was assembled
using a manual tissue arrayer (Beecher Instruments,
Sun Prairie, WI). H&E and p63/-methylacyl-CoA race-
mase IHC double staining to control the histological
diagnosis and E-cadherin and vimentin IHC were per-
formed on a Discovery-XT staining device (Ventana,
Tucson, AZ). The following antibodies were used: anti-
E-cadherin (1:50; Dako), anti-vimentin (1:300; Dako,
Glostrup, Denmark), anti-p63/-methylacyl-CoA race-
mase (1:200; Dako), and anti-p63 (1:100; Sigma-Al-
drich). In addition, FFPE PC3, DU-145, PC3-DR, andDU-145-DR were also stained with E-cadherin (1:50;
Dako) and vimentin (1:300; Dako) antibodies. Micro-
scope images were taken with a Zeiss Imager Z2 mi-
croscope (Zeiss, Vienna) equipped with a Pixelink PL-
B622-CU camera (Canimpex Enterprises Ltd, Halifax,
NS, Canada). The IHC evaluation was performed by a
uropathologist (G.S.) using the semiquantitative scor-
ing system, quick score, combining the proportion of
positive cells and the average staining intensity.21 E-
cadherin expression of PC3, DU-145, PC3-DR, and
DU-145-DR cells was quantified using HistoQuest soft-
ware version 3.0 (Tissue Gnostics, Vienna).
FACS Analysis of Stem Cell Markers
For the measurement of stem cell markers, cultivated
cells were harvested and washed in PBS (PAA Labo-
ratories, Pasching, Austria). Before staining, the cells
were blocked in FACS buffer containing 6 g/mL Hu-
man IgG1 (Dinova, Königswinter, Germany). The cells
were centrifuged at room temperature. The cell pellets
were resuspended in 300 L of FACS buffer. For each
staining, 10 L of the antibody and 25 L of the cell
suspension were used and incubated for 30 minutes at
4°C. After incubation, the cells were washed with 1.5
mL of FACS buffer and centrifuged at 300  g for 10
minutes at 4°C. The supernatant was aspirated, and
cells were resuspended in 500 L of FACS buffer.
Measurement was performed in a BD FACS Calibur
flow cytometer (Becton Dickinson). The analysis was
performed by Cell Quest software version 4.0.1 (Bec-
ton Dickinson). Areas were determined by analysis of
isotype-specific stains and single stains. The following
antibodies were used for analysis: anti-human
CD133/1 (ACC133)–phycoerythrin (PE; Miltenyi Biotec,
Bergisch Gladbach, Germany), anti-human CD44-
PerCP-Cy5.5 (488/695 nm) (Becton Dickinson), fluo-
rescein isothiocyanate mouse anti-human CD24 (Bec-
ton Dickinson), fluorescein isothiocyanate mouse IgG1
 isotype control (Becton Dickinson), monoclonal anti-
human integrin  2, anti-human CD49b-PE (R&D Sys-
tems, Minneapolis, MN), mouse IgG1-PE (Miltenyi Bio-
tec), PerCP-Cy5.5 mouse IgG2b, isotype control
(Becton Dickinson), and anti-human prostate stem cell
antigen (PSCA; 7F5)–PE (Santa Cruz Biotechnology).
Re-Attachment Assay
The 96-well plates were coated with laminin (coverage,
1.5 g/cm2; Sigma-Aldrich), fibronectin (coverage, 3 g/
cm2; Becton Dickinson), Matrigel (4%; Becton Dickin-
son), collagen IV (coverage, 6 g/cm2; Sigma-Aldrich),
HBMEC-60, or PF-172. The cells were trypsinized and
stained with Calcein AM Solution (Sigma-Aldrich) for 1
hour. Stained cells were washed twice with PBS and
counted using a CASY cell counter system (Schärfe Sys-
tem, Reutlingen, Germany). A total of 3  104 cells per
well were seeded onto coated or uncoated wells and
allowed to attach for 1 hour. Subsequently, the plates
were washed twice with PBS. The cells were then lysed
in 100 L of PBS containing 10% Triton X-100 for 15
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surement with extinction/emission at approximately
494/517 nm using a Chameleon plate reader (HVD Life
Sciences, Vienna). The results were normalized to the
light emission of 3  104 stained cells of each cell line
counted.
Adhesion Assay
Cells were seeded onto 12-well plates and allowed to
attach for 24 hours. On the next day, the cells were
stained with Calcein AM Solution (Sigma-Aldrich) for 1
hour and washed with PBS. Trypsin, 200 L, was
added for 120 seconds. The reaction was stopped by
adding 500 L of medium. After 1 minute of shaking,
detached cells were removed. The remaining cells
were lysed in 700 L of PBS/10% Triton X-100 for 15
minutes. Each lysate, 100 L, was transferred onto
96-well plates in triplicate and subjected to measure-
ment with extinction/emission at approximately 494/
517 nm using a Chamaeleon plate reader. The results
were normalized to lysates of non-trypsinized control
wells of the respective cell line.
Migration and Invasion Assays
Migration and invasion were assayed in Fluoro Blok indi-
vidual inserts (pore size, 8 m thick) in a 24-well com-
panion plate (both from Becton Dickinson). For invasion,
inserts were coated with 30 L of Matrigel (30% in me-
dium; Becton Dickinson) for 2 hours before use. A total of
2.5  104 cells were seeded onto the apical surface of
the inserts in full growth medium. To attract cells to mi-
grate or invade, the basal chamber of the wells was filled
with 650 L of medium containing 30% FCS. The cells
were allowed to migrate or invade for 48 hours and sub-
sequently stained with Calcein AM Solution (Sigma-Al-
drich) for 1 hour. Migration or invasion was measured
using a microplate reader (Tecan, Grödig, Austria) with
extinction/emission of 494/517 nm. To calculate the per-
centage of migrated or invaded cells, the light emission
of wells without insert, but the same number of cells, was
set to 100%.
Statistical Analysis
The analysis was performed with Graph Pad Prism soft-
ware version 4.0 (Graph Pad Software, La Jolla, CA). For
all experiments, gaussian distribution was determined
using a Kolmogorov-Smirnov test. Differences between
treatment groups were analyzed using a Student’s t-test.
P  0.05 was considered significant. In addition, statis-
tical analysis was controlled using the Mann-Whitney U-
test, a nonparametric test identifying statistically signifi-
cant differences independent of sample distribution and
variance between the samples. All differences high-
lighted by asterisks were statistically significant and en-coded in figures. Data are presented as mean  SD
unless otherwise stated.
Results
Alterations in Proliferation and Apoptosis in
Docetaxel-Resistant Cells
The resistance of the established sublines PC3-DR and
DU-145-DR was determined by testing cell proliferation
and viability in the presence of increasing concentrations
of docetaxel (up to 100 nmol/L) by [3H]thymidine incor-
poration and MTT assay, respectively (see Supplemental
Figure S1, A and B, at http://ajp.amjpathol.org). Both pa-
rental cell lines were sensitive to docetaxel and showed a
decreased viability and proliferation at a concentration of
5 nmol/L docetaxel. In contrast, PC3-DR cells showed no
changes in cell viability and proliferation, even with the
highest docetaxel concentration. When parental and re-
sistant PC3 cells were treated with 12.5 nmol/L docetaxel
(Figure 1, A and B), we detected a significant decrease in
proliferation and cell viability in PC3, but not in PC3-DR,
cells. DU-145-DR cells showed a decreased basal pro-
liferation and viability compared with DU-145 cells in the
absence of docetaxel. However, we observed a signifi-
cantly higher proliferation and cell viability compared with
their parental counterparts in the presence of 12.5 nmol/L
docetaxel. The MTT assay results were confirmed by
apoptosis measurement (Figure 1C). After treatment with
12.5 nmol/L docetaxel for 3 days, light microscopy im-
ages (see Supplemental Figure S1D at http://ajp.
amjpathol.org) were taken and the percentage of apop-
totic cells was assessed and quantified (Figure 1C; see
also Supplemental Figure S1C at http://ajp.amjpathol.
org). Propidium iodide staining and FACS analysis re-
vealed an increase in apoptosis (from 2.95% to 15.53% in
PC3 and from 2.26% to 52.02% in DU-145 cells). In
contrast, PC3-DR cells showed no change in the apop-
tosis rate (from 1.13% to 1.15%), and in DU-145-DR cells,
there was a slight increase in the percentage of apoptotic
cells (from 3.49% to 8.01%).
EMT Occurs during the Selection Process with
Docetaxel
Resistant cells, especially PC3-DR, were, in general,
smaller and showed a more elongated shape than their
parental counterparts. Therefore, we hypothesized that
docetaxel-resistant cells changed their morphological
characteristics to a mesenchyme-like phenotype (Figure
1D). The screening of 84 EMT-associated genes by an
EMT-specific PCR array revealed 10 genes that were
significantly up- or down-regulated in both docetaxel-
resistant cell lines (see Supplemental Table S2 at http://
ajp.amjpathol.org). Of these 10 genes, CDH1 (E-cadherin)
was down-regulated, whereas several EMT markers, VIM
(vimentin), ZEB1 (zinc finger E-box–binding homeobox
1), and ZEB2 (zinc finger E-box–binding homeobox 2),
at leas
s. ABS, a
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Therefore, PCR array results were, in addition, verified
with a second set of primers by RT-qPCR (Figure 2A).
Figure 1. PC3-DR and DU-145-DR cells are less sensitive to docetaxel and hav
and cell viability (B) in parental and docetaxel-resistant PC3 and DU-145 c
incorporation. Cell viability was determined by the MTT assay. C: Confirmation o
after propidium iodide staining. The results represent mean values  SEM from
different cell morphological characteristics compared with the parental cell lineMoreover, Western blot analysis revealed a similarchange in E-cadherin and vimentin expression at the
protein level (Figure 2B). Furthermore, reduced E-cad-
herin and increased vimentin protein expression levels
chyme-like morphological characteristics. The measurement of proliferation (A)
own. Cellular proliferation was assessed by measurement of [3H]thymidine
d cell viability. The percentage of apoptotic cells was assessed by flow cytometry
t three independent experiments. *P  0.05. D: Docetaxel-resistant cells have
bsorbance; sub, standard for apoptosis analysis.e mesen
ells is sh
f reducewere confirmed with a second set of antibodies by IHC
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(Figure 2C).
Decreased Expression of miR-200c and
miR-205 Is Responsible for E-Cadherin Loss
in Chemotherapy-Resistant Cells
The expression of ZEB1 and ZEB2, which, in turn, regu-
lated the expression of E-cadherin, was under tight con-
trol by miR-200 family members, especially miR-200c
and miR-205.14,15 To better understand the mechanism
of the observed E-cadherin decrease in docetaxel-resis-
tant cells, we measured miR-200c and miR-205 expres-
sion levels (Figure 2D) in parental and docetaxel-resis-
tant sublines. PC3-DR cells showed a significantly
reduced expression of miR-200c and miR-205 compared
with parental PC3 cells. The expression of miR-200c was
also reduced in DU-145-DR cells, whereas the expres-
sion of miR-205 was under the detection limit in DU-145
and DU-145-DR cells. To investigate the possibility that
short-term docetaxel treatment caused down-regulation
of both miRNAs, we measured their expression after 48
and 72 hours of treatment. Although a minor inhibitory
effect was observed, statistical significance was notable
only at one time point in PC3 cells (see Supplemental
Figure S2B at http://ajp.amjpathol.org). Therefore, we
concluded that inhibition of both miR-200 family mem-
bers occurred after long-term treatment with docetaxel
during the selection process. Transfection of both miRNAs
for 3 days resulted in a significantly increased expression
of E-cadherin and a significantly diminished expression
of ZEB1 and ZEB2 mRNAs in both resistant sublines
(Figure 3A). A prolonged treatment with miRNAs for 6
days resulted in elevated E-cadherin protein levels (Fig-
ure 3B) and an increase in the percentage of apoptotic
cells (see Supplemental Figure S2, C and D, at http://
ajp.amjpathol.org). Apoptosis was determined by mea-
surement of cleaved poly (ADP-ribose) polymerase (Fig-
ure 3B), confirmed, and quantified (Figure 3C) by flow
cytometry.
Docetaxel-Resistant Cells Are Able to Form
Colonies and Spheroids
Despite changed cell morphological characteristics and
low E-cadherin expression caused by the EMT, do-
cetaxel-resistant cells were still able to form colonies in a
Table 1. Selected Significantly Up- and Down-Regulated Genes
in Docetaxel-Resistant Prostate Cancer Cells Compared
with Their Parental Counterparts
Gene of interest
Fold regulation
PC3-DR DU-145-DR
VIM 4.2136 2.3057
ZEB1 4.7775 4.1611
ZEB2 5.4294 12.4165
CDH1 12.1887 48.2364two-dimensional colony formation assay. Colonies of do-cetaxel-resistant cells were, in general, smaller than
those of parental cells. DU-145-DR cells formed fewer
colonies than their parental counterparts in the absence
of docetaxel. However, in contrast to parental cells,
PC3-DR and DU-145-DR cells formed colonies in the
presence of 12.5 nmol/L docetaxel (Figure 4, A and B). In
addition, single cells were seeded in Matrigel and grown
spheroids were harvested. In spheroids, E-cadherin and
vimentin protein expression levels were determined (Fig-
ure 4, C and D) by IHC and revealed a similar E-cadherin
and vimentin staining pattern compared with single cells
grown in a monolayer (Figure 2C).
Increased Stemness Is a Characteristic Feature
of Docetaxel-Resistant Cells
Cells that undergo EMT might display an increased ex-
pression of stem cell markers. To investigate this issue in
docetaxel-resistant cells, we determined the expression
of CD24, CD44, CD49b, CD133, and PSCA. Parental and
docetaxel-resistant cells expressed the stem cell markers
CD44 and CD49b (Figure 5A). Docetaxel-resistant cells
contained an increased CD24low-CD44high subpopula-
tion compared with their parental counterparts (Figure
5B). Moreover, cells of the CD44high subgroup showed a
more intense CD49b staining compared with the CD44low
subgroup in parental and docetaxel-resistant cells (see
Supplemental Figure S3A at http://ajp.amjpathol.org). All
screened cell lines were negative for CD133 (see Sup-
plemental Figure S3B at http://ajp.amjpathol.org). The
prostate stem cell marker, PSCA, was expressed in all
cell lines. However, no significant difference in its expres-
sion was observed in docetaxel-resistant cells (see Sup-
plemental Figure S3C at http://ajp.amjpathol.org).
Increased Invasive Potential of Docetaxel-
Resistant Prostate Cancer Cells
Because of their morphological characteristics, do-
cetaxel-resistant cells detach more easily from the sur-
face in a specifically established adhesion assay (Figure
6A). At the same time, they had the same or even higher
ability to attach to extracellular matrix proteins, such as
laminin, fibronectin, collagen IV, and Matrigel (Figure 6B).
Moreover, PC3-DR and DU-145-DR cells had a similar or
higher affinity to attach to HBMEC-60 and PF-172 com-
pared with parental cells (Figure 6C). The ability to de-
tach from surfaces, combined with the higher re-attach-
ment potential, resulted in an increased migratory and
invasive behavior (Figure 6D).
E-Cadherin Expression Is Reduced in Patients
after Neoadjuvant Docetaxel Chemotherapy
To prove that a lower E-cadherin expression after do-
cetaxel treatment was not limited to in vitro conditions, we
determined E-cadherin expression in benign and malig-
n was d
TATA-B
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pose, a TMA was established. In total, 28 patients were
selected (see Supplemental Table S1 at http://ajp.
amjpathol.org). Of these patients, 14 received neoadju-
vant docetaxel chemotherapy before radical prostatec-
tomy. For analysis, both patient groups were divided into
Figure 2. Altered expression of EMT markers in docetaxel-resistant cells. A:
SEM from at least three independent experiments. B: E-cadherin and vimenti
C: Different E-cadherin and vimentin protein expression was confirmed by
version 3.0. D: Total RNA was isolated, and miR-200c and miR-205 expressio
and SNORD48. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TBP,low (7) and high (7) Gleason score subgroups. Incontrol patients without chemotherapy, no significant dif-
ference in E-cadherin expression was detected. How-
ever, patients with a high Gleason score in the chemo-
therapy group showed significantly lower E-cadherin
expression in malignant compared with benign areas and
with malignant areas of patients with low Gleason scores
ation of PCR array results by RT-qPCR. The results represent mean values 
n expression was determined and quantified by using Western blot analysis.
e percentage of stained cells was determined by using HistoQuest software
etermined by RT-qPCR and normalized to small nucleolar RNAs, SNORD44
ox–binding protein. *P  0.05 (A, B, and D), **P  0.01 (B).Confirm
n protei
IHC. Th(Figure 7, A and C). Strikingly, a direct comparison be-
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AJP December 2012, Vol. 181, No. 6Figure 3. Decreased expression of miR-200c and miR-205 is responsible for E-cadherin loss and a crucial factor to circumvent apoptosis. A: The expression of
E-cadherin, ZEB1, and ZEB2 mRNA in docetaxel-resistant PC3 and DU-145 cells after transfection with miR-200c and/or miR-205 for 3 days. B: Representative
Western blot analyses for E-cadherin and cleaved poly(ADP-ribose) polymerase (PARP) expression after double transfection with 25 nmol/L miR-200c and miR-205
for 6 days in the presence of docetaxel. C: The percentage of apoptotic cells was assessed by flow cytometry after propidium iodide staining. RT-qPCR and FACS
analysis results represent mean values  SEM from at least three independent experiments. *P  0.05, **P  0.01, and ***P  0.001. D: Proposed model for
docetaxel-triggered EMT in docetaxel-resistant cells. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; neg, negative; sub, standard for apoptotic analysis;
TBP, TATA-Box–binding protein.
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AJP December 2012, Vol. 181, No. 6Figure 4. Despite decreased E-cadherin expression, docetaxel-resistant cells are still able to form colonies and spheroids. Clonogenic assay for parental and
docetaxel-resistant PC3 (A) and DU-145 (B) cells in the presence or absence of 12.5 nmol/L docetaxel. Colony formation ability was assessed by counting the
number of colonies formed after 12 days. PC3-DR (C) and DU-145-DR (D) cells are also able to form spheroids. Original magnification, 40. IHC reveals a similar
E-cadherin and vimentin staining pattern compared with single cells grown in a monolayer. Original magnification, 400. *P  0.05, **P  0.001.
compa
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AJP December 2012, Vol. 181, No. 6tween patients with a high Gleason score of both groups
revealed significantly lower E-cadherin expression in pa-
tients treated with docetaxel (Figure 7, B and C). More-
over, when patients were compared according to tumor
recurrence, a reduced E-cadherin expression was ob-
served in tissues from individuals who experienced re-
lapse (Figure 7D). Furthermore, patients were stratified
according to tumor relapse in the control and chemother-
apy groups. E-cadherin expression was significantly
lower in specimens from patients who received docetaxel
treatment (Figure 7D). We also performed vimentin stain-
ing of our TMA obtained from patients with prostate can-
cer (see Supplemental Figure S4B at http://ajp.amjpathol.
org). Vimentin was expressed in benign tissue in the
stromal compartment and in both malignant epithelium
and adjacent stroma.
Discussion
Treatment with docetaxel is the preferred chemothera-
peutic option for different types of cancer. However, it
provides only a modest survival benefit, with most pa-
tients experiencing tumor progression. To gain more in-
sight into the molecular changes that lead to or are as-
sociated with docetaxel insensitivity, we have generated
and characterized resistant PC3 and DU-145 sublines. In
several laboratories, docetaxel-resistant cells have been
established to address the role of other mechanisms
in the development of chemotherapy resistance.1,22,23 In
those publications, increased clusterin expression was
observed in their docetaxel-resistant cell lines. Patterson
et al1 also reported an induced expression of STAT1 and
hypothesized a novel role for both proteins in chemother-
Figure 5. Increased expression of stem cell markers CD44 and CD49b. An
DU-145-DR cells have an increased CD24low and CD44high cell subpopulation
compared with CD44low cells.apy resistance. Other researchers showed an associa-tion between high clusterin protein levels and increased
Akt phosphorylation. The findings of all three groups are
in line with our observations. We were able to confirm an
increased expression of STAT1 and clusterin and an in-
creased basal phosphorylation of Akt in docetaxel-resis-
tant PC3 cells (see Supplemental Figure S2A at http://
ajp.amjpathol.org), thus suggesting that observed chan-
ges are a common phenomenon and independent of cell
culture conditions in individual laboratories.
In contrast to parental cells, PC3-DR and DU-145-DR
sublines have different morphological characteristics. We
prove that the transformation to a mesenchymal pheno-
type occurs during the selection process with docetaxel.
The expression of the main EMT marker, E-cadherin, was
significantly reduced in docetaxel-resistant cells in vitro
and in patients with prostate cancer who received neo-
adjuvant chemotherapy with docetaxel. Several groups
have already reported a reduced E-cadherin expression
during cancer progression. In addition, they observed an
inverse correlation between E-cadherin expression and
patient survival.24,25 In line with these findings, our TMA
data also indicate significantly reduced E-cadherin ex-
pression in patients after neoadjuvant chemotherapy.
These data are additionally supported by observations
that patients with tumor relapse had a significant reduc-
tion of E-cadherin expression. Therefore, this kind of ther-
apy may have previously unrecognized disadvantages.
However, we are aware of the low patient number in our
study. In concordance with our conclusions, recent find-
ings linked high E-cadherin expression within the tumor
with a good prognosis and sensitivity to therapy. In the
literature, high E-cadherin expression and an epithelial
cancer cell phenotype are associated with sensitivity to
expression of specific stem cell markers by FACS analysis. A: PC3-DR and
red with parental cells. B: CD44high cells have a more intense CD49b stainingalysis ofepidermal growth factor receptor inhibitors in urothelial
ability to
y behav
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duced E-cadherin expression in patient samples after
chemotherapy, thus suggesting that the therapy itself can
have a negative influence on E-cadherin expression. Sim-
ilar to our results, cisplatin treatment of primary and met-
astatic epithelial ovarian carcinomas has generated re-
sidual cells with reduced E-cadherin expression and a
mesenchymal stem cell-like profile.28 However, to our
knowledge, we are the first group that demonstrated a
direct influence of prolonged docetaxel treatment on E-
cadherin expression in vitro and in vivo.
Tumors with a mesenchymal-like phenotype are asso-
ciated with poor prognosis and high mortality rates.
These tumors frequently express the E-cadherin repres-
sor, ZEB2, that at the same time protects tumor cells from
DNA damage-induced apoptosis.29 In line with those ob-
servations, we were able to detect an increased expres-
sion of ZEB1, ZEB2, and vimentin in docetaxel-resistant
cells. ZEB1 and ZEB2 are repressors of E-cadherin,
whereas ZEB2 has directly interacted with the vimentin
promoter, thus increasing vimentin expression.30 On the
other hand, it is well-known that the transcriptional re-
pressors Snail and Twist1 can also block expression of
E-cadherin.9 However, Twist1 was not expressed in DU-
145 or DU-145-DR cells, and expression of Snail was not
significantly changed. PC3-DR cells had a slight increase
of Twist1 and Snail (see Supplemental Figure S4A at
http://ajp.amjpathol.org). Because of these different ex-
pression patterns, we propose that ZEB1 and ZEB2 are
Figure 6. Docetaxel-resistant cells have a highly invasive potential. A: Compar
adhesion assay. B and C:Docetaxel-resistant cells have the same or even higher
assay. D: Migration and invasion assays prove an altered invasive and migratorthe main drivers of E-cadherin repression in our do-cetaxel-resistant cell lines. Recent publications have
identified miR-200 family members, miR-200c and miR-
205, as key regulators of EMT. They enforce the epithelial
phenotype by repression of ZEB1 and ZEB2. After sel-
ection with docetaxel, miR-200c expression was signi-
ficantly reduced in both docetaxel-resistant cell lines.
Furthermore, miR-205 levels declined in chemotherapy-
resistant PC3 cells, whereas miR-205 expression was
undetectable in DU-145 and DU-145-DR cells. These
results are consistent with the observations of Bhatnagar
et al,31 who also did not observe miR-205 expression in
the DU-145 cell line. Mechanistically, transfection of both
miRNAs resulted in restored E-cadherin expression, ac-
companied by increased apoptosis, in docetaxel-resis-
tant cells. These data suggest that reduced miR-200c
and miR-205 levels during chemotherapy are crucial for
cancer cell survival and drug resistance. Furthermore, we
show that the levels of transcription factors ZEB1 and
ZEB2 are down-regulated on transfection of either miR-
200c or miR-205. Based on these experiments, our pro-
posed mechanism of miRNA reduction, causing EMT in
docetaxel-resistant cells, is shown in Figure 3D. Similar to
our observations, miR-200c and miR-205 functioned as
tumor suppressors in various neoplasms.32–34 This was
supported by observations that both miRNAs have inhib-
itory functions on cellular invasiveness and migration.
miR-205 can influence migration and invasion by down-
regulation of the protein kinase C or low-density lipopro-
tein receptor–related protein 1.35,36 Furthermore, Jur-
parental cell lines, docetaxel-resistant cells detach easier from the surface in an
attach to extracellular matrix proteins, HBMEC-60, and PF-172 in an attachment
ior of docetaxel-resistant cells. *P  0.05, **P  0.01, and ***P  0.001.ed withmeister et al37 showed that miR-200c is able to
se. Patie
, **P  0
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regulatory proteins FHOD1 and PPM1F. In contrast to
findings by Zemskova et al,38 who report on up-regula-
tion of the prosurvival PIM1 kinase after some hours of
docetaxel treatment, miRNA regulation seems to be a
rather long-term effect of docetaxel. The exact underlying
mechanism should be a subject of further studies. How-
ever, epigenetic changes might be considered respon-
sible for this long-term regulation of miRNAs by do-
cetaxel, as described in pancreatic stem cells.39
An important finding of the present study is that the
percentage of cells with a stem cell-like phenotype is
increased in chemotherapy-resistant prostate cancer
models. Several reports provided evidence that EMT is a
critical factor for invasion and migration and a key event
in tumor recurrence, which is believed to be tightly linked
to cancer stem cells.18,40,41 EMT can favor prostate can-
cer cells with stem cell–progenitor-like properties that
differentially express markers, such as CD24, CD44,
CD49b, CD133, and PSCA.41–44 CD49bhigh/CD44high/
CD133high prostate cancer cells show enhanced clono-
genic potential. Furthermore, Patrawala et al45 reported
that CD44high prostate cancer cells have an increased
invasive and metastatic potential compared with CD44low
Figure 7. E-cadherin protein expression is significantly lower in malignant ti
expression. A: In the patient control group, no significant difference in E-
chemotherapy have a significantly lower E-cadherin expression in malignan
Gleason score. B: Patients with a high Gleason score in the chemotherapy g
a high Gleason score in the control group. C: Representative cores of the TM
D: E-cadherin expression is significantly lower in patients with tumor relap
compared with relapse-free patients in the chemotherapy group. *P  0.05cells. Those findings were supported by Li et al,46 whodetected CD24low-CD44high breast cancer cells that were
resistant to neoadjuvant chemotherapy and human epi-
dermal growth factor receptor-2 inhibition. In addition,
they reported that chemotherapy resulted in an increase
of CD24low-CD44high cells and suggested that such an
increase is a potentially important mechanism of ac-
quired drug resistance.46 Our results are in line with
those observations. We were able to detect an increased
CD24low-CD44high cell population in both docetaxel-re-
sistant models. Moreover, CD44high cells had more in-
tense CD49b staining compared with CD44low cells in
parental and docetaxel-resistant cells. Elevated CD49b
expression is also associated with increased invasive-
ness. Yang et al47 proposed that CD49b is a key regula-
tor of hepatocarcinoma cell invasion across the fibrotic
matrix microenvironment. In functional assays, we were
able to confirm an increased migratory and invasive be-
havior, as well as a strong affinity of docetaxel-resistant
cells to bind to extracellular matrix proteins, endothelial
cells, and prostate fibroblasts. However, we could not
observe any differences in PSCA expression between
parental and docetaxel-resistant cells, whereas CD133
staining was negative for all investigated cells. The role of
CD133 in prostate cancer biological characteristics is a
patients with prostate cancer after chemotherapy. TMA results for E-cadherin
expression is detected. Patients with a high Gleason score who received
ompared with benign areas and with malignant areas of patients with a low
ve a significantly lower E-cadherin expression compared with patients with
groups. Original magnification, 20/0.5 digital camera. Scale bar  100 m.
nts with tumor relapse have a significantly reduced E-cadherin expression
.01, and ***P  0.001. BE, benign; CA, cancer.ssue of
cadherin
t areas c
roup ha
A for allsubject of discussion. CD133high cells express the andro-
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AJP December 2012, Vol. 181, No. 6gen receptor.48 Our observations show that neither an-
drogen receptor negative parental nor docetaxel-resis-
tant cells express CD133. The androgen signaling
pathway is active in patients in whom chemotherapy
failed. On the other hand, manipulations in androgen
levels are associated with the appearance of a mesen-
chymal phenotype in prostate cancer.49,50 EMT reported
herein cannot be attributed to any influence of androgen
because both cell sublines are androgen receptor neg-
ative. In addition, enhancement of a stem cell-like popu-
lation by chemotherapeutics is not limited to docetaxel.
Doxorubicin-selected breast cancer cells also displayed
a CD24low-CD44high phenotype.51 Therefore, new gener-
ations of chemotherapeutics should be examined for their
effects on EMT. For example, CD44-positive cell popula-
tions were reduced by the dual phosphatidylinositol 3-ki-
nase/mammalian target of rapamycin inhibitor, NVP-BEZ
235, in prostate cancer.52 The appearance of CD44
splice variants has been well documented in human
prostate cancer.53 Based on the data available in the
literature, quantitative analysis of CD44 expression in a
subpopulation of stem cells in human specimens may not
necessarily yield reliable data.53 Such analysis may be
complicated by the fact that standard CD44 isoform ex-
pression is down-regulated in prostate cancer, whereas
some of the isoforms may be expressed at a higher level.
Our TMA findings on expression of the mesenchymal
marker, vimentin, are in concordance with results re-
ported by others.54,55 The expression of vimentin in a
small percentage of tumor cells was observed solely in a
subgroup of poorly differentiated prostate cancers,
whereas it was much higher in metastatic samples.55
Previous studies on CD44 and vimentin expression in
prostate cancer indicate differences in expression of
these markers between cellular models and tissue spec-
imens.
Taken together, the results of the present and other
studies are relevant for development of novel experimen-
tal therapies in prostate cancer. Our findings prove that
docetaxel treatment leads to a clonal selection of highly
invasive prostate cancer cells characterized by a mes-
enchymal and stem cell-like phenotype. Furthermore, we
speculate that this mechanism is at least in part respon-
sible for chemotherapy failure, with implications for the
development of novel therapeutics.
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